ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders –– Topline Data Expected Mid-Year 2025 –MELBOURNE, Australia and ...

Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) has announced the completion of its last patient visit in the ATH434-202 ...

Alterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy.

“ATH434 has demonstrated significant slowing of clinical progression and a favourable safety profile in Multiple System Atrophy (MSA), a rare and rapidly progressive disease. We will use funds ...

Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open ...

"We are grateful for the strong response from the investment community and are proud to welcome a number of leading domestic and international institutions as shareholders in support of Alterity as we ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). "Following the positive ...

ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders - - Topline Data Expected Mid-Year 2025 - MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE ...